These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 25128047)

  • 21. Prostate-specific antigen control with low-dose adjuvant radiotherapy for high-risk prostate cancer.
    Macdonald OK; Lee RJ; Snow G; Lee CM; Tward JD; Middleton AW; Middleton GW; Sause WT
    Urology; 2007 Feb; 69(2):295-9. PubMed ID: 17320667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective.
    de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP
    Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
    D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
    J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Robustness of ProsVue linear slope for prognostic identification of patients at reduced risk for prostate cancer recurrence: Simulation studies on effects of analytical imprecision and sampling time variation.
    Sarno MJ; Davis CS
    Clin Biochem; 2012 Nov; 45(16-17):1479-84. PubMed ID: 22687714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
    Buskirk SJ; Pisansky TM; Schild SE; Macdonald OK; Wehle MJ; Kozelsky TF; Collie AC; Ferrigni RG; Myers RP; Prussak KA; Heckman MG; Crook JE; Parker AS; Igel TC
    J Urol; 2006 Sep; 176(3):985-90. PubMed ID: 16890677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant radiotherapy after radical prostatectomy: evidence and analysis.
    Raldow A; Hamstra DA; Kim SN; Yu JB
    Cancer Treat Rev; 2011 Apr; 37(2):89-96. PubMed ID: 20667660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.
    Barocas DA; Bensink ME; Berry K; Musa Z; Bodnar C; Dann R; Ramsey SD
    Int J Technol Assess Health Care; 2014 Oct; 30(4):345-53. PubMed ID: 25399914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External validation of University of California, San Francisco, Cancer of the Prostate Risk Assessment score.
    Zhao KH; Hernandez DJ; Han M; Humphreys EB; Mangold LA; Partin AW
    Urology; 2008 Aug; 72(2):396-400. PubMed ID: 18372031
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.
    Nieder AM; Porter MP; Soloway MS
    J Urol; 2008 Nov; 180(5):2005-9; discussion 2009-10. PubMed ID: 18801517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Salvage radiotherapy for prostate-specific antigen relapse after radical prostatectomy for prostate cancer: a single-center experience.
    Yoshida T; Nakayama M; Suzuki O; Matsuzaki K; Kobayashi Y; Takeda K; Arai Y; Kakimoto K; Nishiyama K; Nishimura K
    Jpn J Clin Oncol; 2011 Aug; 41(8):1031-6. PubMed ID: 21693484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy.
    Suardi N; Gallina A; Lista G; Gandaglia G; Abdollah F; Capitanio U; Dell'Oglio P; Nini A; Salonia A; Montorsi F; Briganti A
    Eur Urol; 2014 Mar; 65(3):546-51. PubMed ID: 23415377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radiation therapy for local recurrence of prostate cancer after radical prostatectomy.
    Takayama TK; Lange PH
    Urol Clin North Am; 1994 Nov; 21(4):687-700. PubMed ID: 7526515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.
    Lester-Coll NH; Goldhaber SZ; Sher DJ; D'Amico AV
    Cancer; 2013 May; 119(10):1808-15. PubMed ID: 23400678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database.
    Moreira DM; Jayachandran J; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Stephenson AJ; Freedland SJ
    BJU Int; 2009 Nov; 104(10):1452-6. PubMed ID: 19466946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
    Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
    J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.
    Wiegel T; Bartkowiak D; Bottke D; Thamm R; Hinke A; Stöckle M; Rübe C; Semjonow A; Wirth M; Störkel S; Golz R; Engenhart-Cabillic R; Hofmann R; Feldmann HJ; Kälble T; Siegmann A; Hinkelbein W; Steiner U; Miller K
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):288-94. PubMed ID: 25445556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal timing of early versus delayed adjuvant radiotherapy following radical prostatectomy for locally advanced prostate cancer.
    Kowalczyk KJ; Gu X; Nguyen PL; Lipsitz SR; Trinh QD; Lynch JH; Collins SP; Hu JC
    Urol Oncol; 2014 Apr; 32(3):303-8. PubMed ID: 24321259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database.
    Macdonald OK; D'Amico AV; Sadetsky N; Shrieve DC; Carroll PR
    Urology; 2007 Jul; 70(1):106-10. PubMed ID: 17656218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer.
    Lobo JM; Trifiletti DM; Sturz VN; Dicker AP; Buerki C; Davicioni E; Cooperberg MR; Karnes RJ; Jenkins RB; Den RB; Showalter TN
    Clin Genitourin Cancer; 2017 Jun; 15(3):e299-e309. PubMed ID: 28089723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.